Sun Pharma Adv.Res.Co.Ltd Share Price Ended Higher to ₹208.85 on M&A News — What It Means for Investors

Sun Pharma Adv.Res.Co.Ltd: what is happening in Tuesday's session

Sun Pharma Adv.Res.Co.Ltd (SPARC) last traded at ₹208.85, +6.00 (+2.96%) against a previous close of ₹202.85, read from the NSE board at the close of the last trading session on Tuesday, 29 September 2026. On the tape the move is inside the stock's usual daily range, so the tape is treating the story as information rather than as a reason to reprice.

The market is closed at the time of writing (Wednesday, 02:35 am IST); the levels below are the close of the Tuesday, 29 September 2026 session.

The story in five lines

• Where it trades: Sun Pharma Adv.Res.Co.Ltd is at ₹208.85, +6.00 (+2.96%) versus the previous close of ₹202.85.
• Why it is moving: a m&a story — one business desk filed on the company in the last few hours.
• Today's band: ₹203.30 to ₹211.00, against an open of ₹204.50 — the stock is defending its opening print.
• Twelve-month context: 27.73% below the ₹289 high and 93.38% above the ₹108 low, so the stock sits in the middle part of its own range.
• Participation: turnover is running at 1.3x the twenty-day average, which is ordinary flow — the move lacks a volume endorsement so far.
• What to watch: the swap ratio and the regulatory approval calendar, which decide when the structure actually takes effect.

The m&a angle

The reason Sun Pharma Adv.Res.Co.Ltd is on the desks in Tuesday's session is a m&a story — reported by one desk so far, with the headlines linked below. A merger or demerger changes the entity being valued, so the price has to reprice against a new set of cash flows and a swap ratio rather than against last quarter's numbers.

Live price snapshot

What changes when the entity itself changes

In a merger, demerger or acquisition the market stops valuing the company it was valuing yesterday. Past quarterly numbers describe an entity that will not exist in the same form, so the price has to be rebuilt around a new set of cash flows, a new debt position and — in a share-swap deal — a fixed exchange ratio that ties this stock's value to another's.

The swap ratio is where most of the day-one move comes from: if the ratio implies a value different from the traded price, arbitrage desks trade the gap until the two converge. After that, the calendar takes over. Board approval is only the first step; competition-authority clearance, creditor and shareholder meetings and tribunal approval each carry their own timeline, and deals routinely take several quarters to become effective.

Sun Pharma Adv.Res.Co.Ltd at ₹208.85, +6.00 on the day, is trading the probability of completion as much as the economics of the combination.

Reading today's session

Sun Pharma Adv.Res.Co.Ltd has traded between ₹203.30 and ₹211.00 in this session against an open of ₹204.50 and a previous close of ₹202.85. That is a band of ₹7.70, or 3.69% of the current price — an ordinary day's spread, so the move is orderly rather than disorderly.

Holding above the open at ₹204.50 matters because it is the level intraday desks use as the session pivot: buyers who entered at the open are in profit, so there is no forced supply from that cohort.

In market-structure terms this is a continuation session, so the prior trend remains the base case until a level breaks.

The headlines behind this post

Headlines are listed for context and link straight to the publisher. The prices, ranges and tables on this page are read independently from exchange data at the timestamp shown.

• Sun Pharma plans ₹10,000 crore bond sale to refinance Organon acquisition loan: Report — Livemint

How the stock has performed

What the returns table is saying

Over the last week Sun Pharma Adv.Res.Co.Ltd has gained +6.50% and over the month +7.11%. Both horizons pointing the same way means the recent move is an extension of the existing trend rather than a reversal.

The twelve-month return of +62.18% is the context long-term holders judge the stock on. After a run of this size, most of the easy re-rating is behind the price, so incremental gains usually have to come from delivered earnings rather than sentiment.

Reading the price against its own ranges

Over the last twelve months the price has covered ₹108 to ₹289. The current level is 56% of the way through that band, 27.73% below the 52-week high and 93.38% above the 52-week low. A mid-range price means neither the bulls nor the bears own the trend yet; the twelve-month extremes are the levels that decide which way the range resolves.

Traded quantity of 14,52,486 shares is 1.34x the 20-day average of 10,81,366. Turnover close to the recent norm suggests an orderly session rather than a scramble, so the move reflects ordinary two-way flow.

What to watch next

For this m&a story specifically, watch the swap ratio and the regulatory approval calendar, which decide when the structure actually takes effect. On the chart, the ₹211.00 high and ₹203.30 low of the last session are the reference levels — a higher low in the next session turns a headline reaction into a trend, a break of that low usually voids it. Participation is the third check: the move needs turnover at or above the stock's own 20-day average of 10,81,366 shares to be read as positioning rather than a squeeze.

So what should shareholders do with this?

For a trader, this is a low-information session: the move sits inside the stock's normal daily spread, so there is no edge in chasing it. Waiting for a close outside ₹203.30–₹211.00 is the cheaper way to be positioned.

For a long-term shareholder, this is an event with an open-ended outcome, and the market is pricing a range rather than a number. The company's own exchange clarification — not the headline — is the document that narrows that range, and it is worth waiting for before adding or trimming.

On risk: this report is a reading of live exchange data at a point in time, and intraday levels change. Position sizing — not conviction about the story — is what determines the outcome of a trade built on a headline, and averaging into a falling price without a change in the underlying facts is how a trade becomes an unintended long-term holding.

Where that leaves the stock

Sun Pharma Adv.Res.Co.Ltd is being bought on a m&a story, and at ₹208.85 the move is not yet backed by turnover above its own average, which is the version of a rally that tends to fade. The day's ₹203.30–₹211.00 band is the frame for the next session, and the swap ratio and the regulatory approval calendar, which decide when the structure actually takes effect is what resolves the story either way.

Where to track SPARC next

Live price, charts and technicals stay on the Sun Pharma Adv.Res.Co.Ltd stock page, and every filed quarter is tabulated on its quarterly results page. Both pages refresh from the exchange feed through the session, so they carry a later reading than this report once the market has moved on.

Frequently asked questions

What is the Sun Pharma Adv.Res.Co.Ltd share price in Tuesday's session?

Sun Pharma Adv.Res.Co.Ltd (SPARC) last traded at ₹208.85, +6.00 (+2.96%) against the previous close of ₹202.85, read from the NSE board at the close of the last trading session on Tuesday, 29 September 2026.

Why is Sun Pharma Adv.Res.Co.Ltd in the news in Tuesday's session?

1 business publisher ran headlines on the company in the last session — a m&a story. Their reports are linked above; the levels and tables here are read independently from exchange data.

What is the 52-week high and low of SPARC?

Over the last twelve months SPARC has traded between a low of ₹108 and a high of ₹289, computed from the adjusted daily series.

Is SPARC up or down in Tuesday's session?

SPARC gained +2.96% in the last session, trading between ₹203.30 and ₹211.00 against an open of ₹204.50.

Is the market open right now?

No. The market is closed at the time of writing (Wednesday, 02:35 am IST); the levels below are the close of the Tuesday, 29 September 2026 session.

Key takeaways

• Last price: ₹208.85 (+2.96%) — higher at the time of writing
• Day range: ₹203.30 – ₹211.00
• 52-week high: ₹289

About this report

Every figure on this page is read from a primary source at the timestamp shown — exchange boards for equities and indices, the exchange bid book for IPOs, published association rates for bullion, and consolidated exchange quotes for crypto — with no estimation or third-party commentary. Historical fields such as trailing returns and 52-week extremes are computed on the adjusted daily series so splits and bonuses do not create false gaps. A timestamp outside market hours reflects the last traded or last published value, not a live tick.

Related live pages

• Sun Pharma Adv.Res.Co.Ltd share price
• Sun Pharma Adv.Res.Co.Ltd quarterly results
• Stocks in news
• Top gainers
• Market dashboard

Sources

• NSE live board data via our exchange data feed
• Headline attribution links above point to the original publishers
• TrendRipperX Sun Pharma Adv.Res.Co.Ltd stock page

“This report is generated automatically from live exchange and official association data at the time stamped above. Prices move continuously — verify on the source before acting. Nothing here is investment advice.”